Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;26(5):433-438.
doi: 10.1002/onco.13752. Epub 2021 Mar 25.

FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer

Luckson Mathieu  1 , Sujay Shah  1 , Lee Pai-Scherf  1 , Erin Larkins  1 , Jonathon Vallejo  1 , Xiaoxue Li  1 , Lisa Rodriguez  1 , Pallavi Mishra-Kalyani  1 , Kirsten B Goldberg  2 , Paul G Kluetz  1   2 , Marc R Theoret  1   2 , Julia A Beaver  1   2 , Richard Pazdur  1   2 , Harpreet Singh  1   2
Affiliations
Review

FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer

Luckson Mathieu et al. Oncologist. 2021 May.

Abstract

The U.S. Food and Drug Administration (FDA) granted approval to atezolizumab and durvalumab in March of 2019 and 2020, respectively, for use in combination with chemotherapy for first-line treatment of patients with extensive stage small cell lung cancer. These approvals were based on data from two randomized controlled trials, IMpower133 (atezolizumab) and CASPIAN (durvalumab). Both trials demonstrated an improvement in overall survival (OS) with anti-programmed death ligand 1 antibodies when added to platinum-based chemotherapy as compared with chemotherapy alone. In IMpower133, patients receiving atezolizumab with etoposide and carboplatin demonstrated improved OS (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.54-0.91; p = .0069), with median OS of 12.3 months compared with 10.3 months in patients receiving etoposide and carboplatin. In CASPIAN, patients receiving durvalumab with etoposide and either cisplatin or carboplatin also demonstrated improved OS (HR, 0.73; 95% CI, 0.59-0.91; p = .0047) with median OS of 13.0 months compared with 10.3 months in patients receiving etoposide and either cisplatin or carboplatin. The safety profiles of both drugs were generally consistent with known toxicities of immune-checkpoint inhibitor therapies. This review summarizes the FDA perspective and data supporting the approval of these two agents. IMPLICATIONS FOR PRACTICE: Effective therapeutic options for small cell lung cancer (SCLC) are limited, and there has been modest improvement in the overall survival (OS) of patients with SCLC over the past 3 decades. The approvals of atezolizumab and of durvalumab in combination with chemotherapy for first-line treatment of patients with extensive stage SCLC represent the first approved therapies with OS benefit for this patient population since the approval of etoposide in combination with other approved chemotherapeutic agents. Additionally, the efficacy results from IMpower133 and CASPIAN lay the groundwork for possible further evaluation in other treatment settings in this disease.

Keywords: Atezolizumab and durvalumab in small cell lung cancer; FDA approval.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

References

    1. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small‐cell lung cancer in the United States over the last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results Database. J Clin Oncol 2006;24:4539–4544. - PubMed
    1. Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol 2019;12:47. - PMC - PubMed
    1. Pleasance ED, Stephens PJ, O'Meara S et al. A small‐cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010;463:184–190. - PMC - PubMed
    1. Abidin AZ, Garassino MC, Califano R et al. Targeted therapies in small cell lung cancer: a review. Ther Adv Med Oncol 2010;2:25–37. - PMC - PubMed
    1. Foster NR, Qi Y, Krook JE et al. Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancer: Findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011;117:1262–1271. - PMC - PubMed

MeSH terms